Drug Trial Radar · NCT05765344
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Mar 15, 2023
Primary completion
Jan 10, 2025
Study completion Jan 13, 2025
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 79 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.
Conditions
- Hepatic Impairment
- Healthy
Interventions
BulevirtideDrug
2 mg administered via subcutaneous injections.
BulevirtideDrug
10 mg administered via subcutaneous injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)Time frame: Day 6: Predose and up to 24 hours postdose
- PK Parameter: Cmax,ss of BLVTime frame: Day 6: Predose and up to 24 hours postdose
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Orange County Research Center
Lake Forest, California
Clinical Pharmacology of Miami, LLC
Miami, Florida
University of Miami
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
Texas Liver Institute
San Antonio, Texas
Pinnacle Clinical Research LLC
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.